Ken Griffin Edwards Lifesciences Corp Put Options Transaction History

Citadel Advisors LLC

9 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q3 2024 Nov 14, 2024	BUY	$59.7 - $93.78 $14.1 Million - $22.1 Million	235,600 Added 47.99%	726,500 $47.9 Million
Q2 2024 Aug 14, 2024	SELL	$84.3 - $94.31 $37.8 Million - $42.3 Million	-448,200 Reduced 47.73%	490,900 $45.3 Million
Q1 2024 May 15, 2024	BUY	$72.54 - $95.56 $20.9 Million - $27.5 Million	288,100 Added 44.25%	939,100 $89.7 Million
Q4 2023 Feb 14, 2024	BUY	$61.71 - $77.76 $26.5 Million - $33.4 Million	429,800 Added 194.3%	651,000 $49.6 Million
Q3 2023 Nov 14, 2023	BUY	$69.28 - $93.38 $7.48 Million - $10.1 Million	108,000 Added 95.41%	221,200 $15.3 Million
Q2 2023 Aug 14, 2023	SELL	$81.41 - $94.33 $40.3 Million - $46.7 Million	-495,100 Reduced 81.39%	113,200 $10.7 Million
Q1 2023 May 15, 2023	BUY	$74.26 - $84.51 $24 Million - $27.3 Million	323,100 Added 113.29%	608,300 $50.3 Million
Q4 2022 Feb 14, 2023	BUY	$68.3 - $87.44 $1.24 Million - $1.58 Million	18,100 Added 6.78%	285,200 $21.3 Million
Q3 2022 Nov 14, 2022	SELL	$82.37 - $107.29 $10.4 Million - $13.5 Million	-126,200 Reduced 32.09%	267,100 $22.1 Million

1,351

455M

9.76M

3.92M

Ticker EW
Exchange NYSE
Sector Healthcare
Industry Medical Devices
Shares Outstandng 618,259,968
Market Cap $41.9B
Description
Edwards Lifesciences Corporation provides products and technologies for structural heart disease, and critical care and surgical monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of heart valves; and transcatheter heart valve repair...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.